A citation-based method for searching scientific literature

Jason F Lee, Ecaterina Berzan, Vikas S Sridhar, Ayodele Odutayo, David Z I Cherney. Endocrinol Metab (Seoul) 2021
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
100

Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study.
George Bakris, Pablo E Pergola, Belkis Delgado, Diyan Genov, Tamar Doliashvili, Nam Vo, Y Fred Yang, James McCabe, Vincent Benn, Bertram Pitt. Hypertension 2021
4
50

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
Krister Bamberg, Ulrika Johansson, Karl Edman, Lena William-Olsson, Susanna Myhre, Anders Gunnarsson, Stefan Geschwindner, Anna Aagaard, Anna Björnson Granqvist, Frédéric Jaisser,[...]. PLoS One 2018
19
50

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury.
Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, Mark Bush, Vincent Benn, Y Fred Yang, Jay Zhang. Front Pharmacol 2021
2
50

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor.
Stefanie Ruhs, Alexander Nolze, Ralf Hübschmann, Claudia Grossmann. J Endocrinol 2017
31
50


Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Ravi B Patel, Sanjiv J Shah, Gregg C Fonarow, Javed Butler, Muthiah Vaduganathan. Curr Heart Fail Rep 2017
13
50

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Gerasimos Filippatos, George L Bakris, Bertram Pitt, Rajiv Agarwal, Peter Rossing, Luis M Ruilope, Javed Butler, Carolyn S P Lam, Peter Kolkhof, Luke Roberts,[...]. J Am Coll Cardiol 2021
7
50

Is aldosterone bad for the heart?
John W Funder. Trends Endocrinol Metab 2004
75
50


Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Patrick Schloemer,[...]. N Engl J Med 2021
17
50

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.
Jana Grune, Niklas Beyhoff, Elia Smeir, Remigiusz Chudek, Annelie Blumrich, Zsofia Ban, Sarah Brix, Iris R Betz, Michael Schupp, Anna Foryst-Ludwig,[...]. Hypertension 2018
43
50

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
Lionel Lattenist, Sebastian M Lechner, Smail Messaoudi, Alan Le Mercier, Soumaya El Moghrabi, Sonia Prince, Norma A Bobadilla, Peter Kolkhof, Frédéric Jaisser, Jonatan Barrera-Chimal. Hypertension 2017
44
50

Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Linda F Fried, Nicholas Emanuele, Jane H Zhang, Mary Brophy, Todd A Conner, William Duckworth, David J Leehey, Peter A McCullough, Theresa O'Connor, Paul M Palevsky,[...]. N Engl J Med 2013
638
50


Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
15
50

Spironolactone for heart failure with preserved ejection fraction.
Bertram Pitt, Marc A Pfeffer, Susan F Assmann, Robin Boineau, Inder S Anand, Brian Claggett, Nadine Clausell, Akshay S Desai, Rafael Diaz, Jerome L Fleg,[...]. N Engl J Med 2014
50

Eplerenone in patients with systolic heart failure and mild symptoms.
Faiez Zannad, John J V McMurray, Henry Krum, Dirk J van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent, Stuart J Pocock, Bertram Pitt. N Engl J Med 2011
50

Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Farzin Beygui, Guillaume Cayla, Vincent Roule, François Roubille, Nicolas Delarche, Johanne Silvain, Eric Van Belle, Loic Belle, Michel Galinier, Pascal Motreff,[...]. J Am Coll Cardiol 2016
52
50


The role of macrophages in hypertension and its complications.
A Justin Rucker, Steven D Crowley. Pflugers Arch 2017
36
50



Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
Karoline Droebner, Mira Pavkovic, Manuel Grundmann, Elke Hartmann, Laura Goea, Johannes Nordlohne, Jürgen Klar, Frank Eitner, Peter Kolkhof. Am J Nephrol 2021
2
50

Mineralocorticoids in the heart and vasculature: new insights for old hormones.
Achim Lother, Martin Moser, Christoph Bode, Ross D Feldman, Lutz Hein. Annu Rev Pharmacol Toxicol 2015
29
50

Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.
Paul Milliez, Xavier Girerd, Pierre-François Plouin, Jacques Blacher, Michel E Safar, Jean-Jacques Mourad. J Am Coll Cardiol 2005
993
50

Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1.
Miki Nagase, Nobuhiro Ayuzawa, Wakako Kawarazaki, Kenichi Ishizawa, Kohei Ueda, Shigetaka Yoshida, Toshiro Fujita. Hypertension 2012
57
50


Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
Peter Kolkhof, Elke Hartmann, Alexius Freyberger, Mira Pavkovic, Ilka Mathar, Peter Sandner, Karoline Droebner, Amer Joseph, Jörg Hüser, Frank Eitner. Am J Nephrol 2021
6
50

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
Bertram Pitt, Gerasimos Filippatos, Mihai Gheorghiade, Lars Kober, Henry Krum, Piotr Ponikowski, Christina Nowack, Peter Kolkhof, So-Young Kim, Faiez Zannad. Eur J Heart Fail 2012
59
50

The evolution of aldosterone antagonists.
Susan M Garthwaite, Ellen G McMahon. Mol Cell Endocrinol 2004
102
50


Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.
Raquel González-Blázquez, Beatriz Somoza, Marta Gil-Ortega, Miriam Martín Ramos, David Ramiro-Cortijo, Elena Vega-Martín, Angela Schulz, Luis Miguel Ruilope, Peter Kolkhof, Reinhold Kreutz,[...]. Front Pharmacol 2018
14
50

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Rajiv Agarwal, Stefan D Anker, George Bakris, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis Ruilope, Martin Gebel, Peter Kolkhof, Christina Nowack,[...]. Nephrol Dial Transplant 2020
12
50


Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Christina Nowack, Peter Kolkhof, Anna C Ferreira, Patrick Schloemer, Gerasimos Filippatos. Am J Nephrol 2019
52
50

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy.
Stephen Orena, Tristan S Maurer, Li She, Rena Eudy, Vincent Bernardo, Darla Dash, Paula Loria, Mary E Banker, Meera Tugnait, Carlin V Okerberg,[...]. Front Pharmacol 2013
36
50

Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.
Gülmisal Güder, Johann Bauersachs, Stefan Frantz, Dirk Weismann, Bruno Allolio, Georg Ertl, Christiane E Angermann, Stefan Störk. Circulation 2007
213
50


Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Rajiv Agarwal, Patrick Rossignol, Alain Romero, Dahlia Garza, Martha R Mayo, Suzette Warren, Jia Ma, William B White, Bryan Williams. Lancet 2019
101
50

Nonsteroidal antagonists of the mineralocorticoid receptor.
Peter Kolkhof, Christina Nowack, Frank Eitner. Curr Opin Nephrol Hypertens 2015
67
50



Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
Lars Bärfacker, Alexander Kuhl, Alexander Hillisch, Rolf Grosser, Santiago Figueroa-Pérez, Heike Heckroth, Adam Nitsche, Jens-Kerim Ergüden, Heike Gielen-Haertwig, Karl-Heinz Schlemmer,[...]. ChemMedChem 2012
128
50

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda, Tomoko Sawanobori. Clin J Am Soc Nephrol 2020
22
50

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Kiyoshi Arai, Tsuyoshi Homma, Yuka Morikawa, Naoko Ubukata, Hiyoyuki Tsuruoka, Kazumasa Aoki, Hirokazu Ishikawa, Makoto Mizuno, Toshio Sada. Eur J Pharmacol 2015
50
50

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Gilles Montalescot, Bertram Pitt, Esteban Lopez de Sa, Christian W Hamm, Marcus Flather, Freek Verheugt, Harry Shi, Eva Turgonyi, Miguel Orri, John Vincent,[...]. Eur Heart J 2014
88
50



Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans-Henrik Parving, Barry M Brenner, John J V McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Akshay S Desai, Maria Nicolaides,[...]. N Engl J Med 2012
779
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.